1
Michael R Myers, Alfred P Spada, Martin P Maguire, Paul E Persons, Asher Zilberstein, Chin Yi Jenny Hsu, Susan E Johnson: Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase. Rhone Poulenc Rorer Pharmaceuticals, Raymond S Parker III, James A Nicholson, Martin F Savitzky, February 3, 1998: US05714493 (79 worldwide citation)

This invention relates to the treatment of intimation in a patient suffering from such disorder. More specifically, the invention relates to mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in the treatment of inflammation.


2
Michel Revel, Asher Zilberstein: Production of recombinant human interferon-beta.sub.2. Yeda Research & Development, Browdy and Neimark, September 10, 1996: US05554513 (51 worldwide citation)

Human interferon-beta.sub.2.sbsb.A and interferon-beta.sub.2.sbsb.B are produced in purified form by recombinant DNA techniques. Two separate human genes have been identified which code for the production of IFN-.beta..sub.2.sbsb.A and IFN-.beta..sub.2.sbsb.B, respectively. The sequence of IFN-.beta ...


3
Michael R Myers, Alfred P Spada, Martin P Maguire, Paul E Persons, Asher Zilberstein, Chin Yi Jenny Hsu, Susan E Johnson: Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase. Aventis Pharmaceuticals, Raymond S Parker III, Peter J Butch, November 11, 2003: US06645969 (31 worldwide citation)

This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compou ...


4
Michel Revel, Asher Zilberstein: Production of recombinant human interferon beta.sub.2.sbsb.B. Yeda Research & Development, Browdy & Neimark, September 10, 1996: US05554514 (1 worldwide citation)

Human interferon-beta.sub.2.sbsb.A and interferon-beta.sub.2.sbsb.B are produced in purified form by recombinant DNA techniques. Two separate human genes have been identified which code for the production of IFN-.beta..sub.2.sbsb.A and IFN-.beta..sub.2.sbsb.B, respectively. The sequence of IFN-.beta ...


5
Timothy A Gillespy, Paul Eynott, Elizabeth M Allen, Kin T Yu, Asher Zilberstein: Kinase inhibitor. Sanofi, Scully Scott Murphy & Presser P C, February 25, 2014: US08658649

The invention is directed to a compound of formula (I): and the prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs. Such a compound has valuable pharmaceutical properties, in particular the ability to inhibit protein kinases.


6
Michael R Myers, Alfred P Spada, Martin P Maguire, Paul E Persons, Asher Zilberstein, Chin Yi Jenny Hsu, Susan E Johnson: Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase. Aventis Pharmacetical Products, Synnestvedt & Lechner, April 9, 2002: USRE037650

This invention relates to the treatment of intimation in a patient suffering from such disorder. More specifically, the invention relates to mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in the treatment of inflammation.


7

8
Michael R Myers, Alfred P Spada, Martin P Maguire, Paul E Persons, Asher Zilberstein, Chin Yi Jenny Hsu, Susan E Johnson: Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase. Synnestvedt Lechner & Woodbridge, January 22, 2004: US20040014774-A1

This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compou ...


9
Ali Ardati, Kimberly Della Penna, Asher Zilberstein: Novel G Protein-coupled receptor, GAVE1. Aventis Pharmaceuticals, Dean H Nakamura, Roylance Abrams Berdo & Goodman, April 3, 2003: US20030064434-A1

Novel GAVE1 polypeptides, proteins and nucleic acid molecules are provided. In addition to isolated, full-length GAVE1 proteins, isolated GAVE1 fusion proteins, antigenic peptides and anti-GAVE1 antibodies are provided. Moreover, GAVE1 nucleic acid molecules, recombinant expression vectors containin ...


10
Tina Garyantes, Zhuyin Li, Yongping Yan, Justin Anthony Yu, Asher Zilberstein: Dna fragmentation assay. Sanofi Aventis, Andrea Q Ryan, Sanofi Aventis Us, September 30, 2010: US20100248224-A1

The present invention provides methods for the detection of agents that modify the formation of DNA fragmentation in cells. The disclosed methods are configured in an assay format amendable to high throughput screening applications.